LIXTE Biotechnology Partners with IBN for Corporate Communications Strategy

LIXTE Biotechnology Holdings Inc. has engaged IBN to assist with its corporate communications strategy. The company is a clinical-stage pharmaceutical company developing cancer therapies that enhance the effectiveness of existing treatments. LIXTE aims to expand the reach and impact of current standards of care without requiring wholesale changes to clinical practice. The company is focused on advancing a first-in-class approach to improve how chemotherapy and immunotherapy perform in cancers with significant unmet medical need.